AARTIDRUGS Aarti Drugs Q3 FY25 results (Oct–Dec 2024) and concall
Aarti Drugs reported a slight revenue decline in Q3 FY25, primarily due to reduced market prices and weaker demand in certain segments. However, gross profit improved, and the company achieved a significant milestone with US FDA approval for its Tarapur API plant, opening new high-margin market opportunities. Management outlined strategic initiatives including green energy adoption, greenfield project commissioning, and capacity expansions, targeting double-digit revenue growth and improved EBITDA margins in the coming years despite short-term challenges.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 598 | 557 |
| EBITDA | 67 | 62 |
| Net profit | 35 | 37 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
